1
|
Alebouyeh M, Almasian Tehrani N, Fallah F, Azimi L, Sadredinamin M, Yousefi N, Ghandchi G, Haji Molla Hoseini M. Protective effects of different lyoprotectants on survival of clinical bacterial isolates in a hospital biobank. Cryobiology 2024; 115:104891. [PMID: 38522663 DOI: 10.1016/j.cryobiol.2024.104891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Revised: 03/04/2024] [Accepted: 03/21/2024] [Indexed: 03/26/2024]
Abstract
Nowadays the significant role of biobanks in medical, diagnostic, industrial, and environmental research is well known. Bacterial biobanks could be used as a good resource for designing new treatments, biomedical and industrial researches, and laboratory diagnostics. To have a collection of bacteria from clinical samples and maintain their long-term viability, their preservation needs appropriate protective agents, like cryoprotectants and lyoprotectants. In this study, we collected and characterized Gram-negative and Gram-positive bacteria carrying important antibiotic resistance markers from different clinical samples of hospitalized children. Sucrose (10%), skimmed milk (10%), skimmed milk plus sodium glutamate (10% + 1%), and bovine serum albumin (BSA, 10%) were used as lyoprotectants during the freeze-drying procedure. The survival rate of the lyophilized samples was calculated by dilution plating and measuring the colony forming unit (CFU) after 3 months of storage. The culture analysis results indicated that 25 of the 27 studied bacterial genera (Dilutions 10-3 to 10-6), including Shigella, Methicillin-resistant S. aureus, Acinetobacter spp., Escherichia spp., Pseudomonas spp., Klebsiella spp., Enterococcus spp., were recovered in cultured fractions from all preservation conditions, while 2 genera were only detected in a single preservation condition (2/27, 7.4%). Based on the results, sucrose (10%) and skimmed milk (10%) presented the most protective features. The survival rates varied significantly according to types of the bacteria. Collectively, our results showed a diversity in the recovery of different bacterial genera after lyophilization. While statistically no significant difference was detected among the studied protective agents, sucrose (10%) and skimmed milk (10%) exhibited more effective lyoprotective properties for both Gram-positive and Gram-negative bacteria among the clinical isolates in our study.
Collapse
Affiliation(s)
- Masoud Alebouyeh
- Pediatric Infections Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Nasim Almasian Tehrani
- Pediatric Infections Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Fatemeh Fallah
- Pediatric Infections Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Medical Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | - Leila Azimi
- Pediatric Infections Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mehrzad Sadredinamin
- Department of Medical Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Neda Yousefi
- Department of Medical Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Ghazale Ghandchi
- Pediatric Infections Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mostafa Haji Molla Hoseini
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
2
|
Mwapagha LM. Why pathogen genomics is crucial in Africa's public health. Afr J Lab Med 2023; 12:2166. [PMID: 37822518 PMCID: PMC10563014 DOI: 10.4102/ajlm.v12i1.2166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Accepted: 08/04/2023] [Indexed: 10/13/2023] Open
Affiliation(s)
- Lamech M Mwapagha
- Department of Biology, Chemistry and Physics, Faculty of Health, Natural Resources and Applied Sciences, Namibia University of Science and Technology, Windhoek, Namibia
| |
Collapse
|
3
|
Weissinger SE, Georgantas NZ, Thierauf JC, Pellerin R, Gardecki E, Kühlinger S, Ritterhouse LL, Möller P, Lennerz JK. Slide-to-Slide Tissue Transfer and Array Assembly From Limited Samples for Comprehensive Molecular Profiling. J Transl Med 2023; 103:100062. [PMID: 36801639 PMCID: PMC10198954 DOI: 10.1016/j.labinv.2023.100062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Revised: 12/28/2022] [Accepted: 01/10/2023] [Indexed: 01/19/2023] Open
Abstract
Tissue microarrays (TMA) have become an important tool in high-throughput molecular profiling of tissue samples in the translational research setting. Unfortunately, high-throughput profiling in small biopsy specimens or rare tumor samples (eg, orphan diseases or unusual tumors) is often precluded owing to limited amounts of tissue. To overcome these challenges, we devised a method that allows tissue transfer and construction of TMAs from individual 2- to 5-μm sections for subsequent molecular profiling. We named the technique slide-to-slide (STS) transfer, and it requires a series of chemical exposures (so-called xylene-methacrylate exchange) in combination with rehydrated lifting, microdissection of donor tissues into multiple small tissue fragments (methacrylate-tissue tiles), and subsequent remounting on separate recipient slides (STS array slide). We developed the STS technique by assessing the efficacy and analytical performance using the following key metrics: (a) dropout rate, (b) transfer efficacy, (c) success rates using different antigen-retrieval methods, (d) success rates of immunohistochemical stains, (e) fluorescent in situ hybridization success rates, and (f) DNA and (g) RNA extraction yields from single slides, which all functioned appropriately. The dropout rate ranged from 0.7% to 6.2%; however, we applied the same STS technique successfully to fill these dropouts ("rescue" transfer). Hematoxylin and eosin assessment of donor slides confirmed a transfer efficacy of >93%, depending on the size of the tissue (range, 76%-100%). Fluorescent in situ hybridization success rates and nucleic acid yields were comparable with those of traditional workflows. In this study, we present a quick, reliable, and cost-effective method that offers the key advantages of TMAs and other molecular techniques-even when tissue is sparse. The perspectives of this technology in biomedical sciences and clinical practice are promising, given that it allows laboratories to create more data with less tissue.
Collapse
Affiliation(s)
- Stephanie E Weissinger
- Institute of Pathology, Alb Fils Clinics GmbH, Göppingen, Germany; Institute of Pathology, University Hospital Ulm, Ulm, Germany
| | - N Zeke Georgantas
- Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
| | - Julia C Thierauf
- Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
| | - Rebecca Pellerin
- Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
| | - Emma Gardecki
- Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
| | | | - Lauren L Ritterhouse
- Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
| | - Peter Möller
- Institute of Pathology, University Hospital Ulm, Ulm, Germany
| | - Jochen K Lennerz
- Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts.
| |
Collapse
|
4
|
Irene C, Elba M, Jiménez JL, Mellado MJ, Muñoz-Fernández MÁ. HIV HGM biobank as a research platform for paediatric infectious diseases and COVID-19 pandemic. AIDS Res Ther 2022; 19:22. [PMID: 35614512 PMCID: PMC9130977 DOI: 10.1186/s12981-022-00448-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Accepted: 04/07/2022] [Indexed: 12/28/2022] Open
Abstract
AIM The initial cases of COVID-19 appeared in December 2019 and Spain was one of the most affected countries during the first wave (March to June). Since then, HIV HGM BioBank has been restructured as an established Paediatrics and Adults HIV_COVID-19 BioBank that aims at the long-term storage of samples obtained from not only HIV-1, but also from COVID-19 patients and HIV-1_COVID-19 coinfected patients. METHODS HIV HGM BioBank holds high quality biological samples from newborns, children, adolescents and adults with their associated clinical data. Research groups trying to establish large networks focused on research on specific clinical problems in epidemiology, biology, routes of transmission and therapies, are potential users of the clinical samples and of associated data of HIV-1_COVID-19 HGM BioBank. RESULTS The HIV HGM BioBank is an academic and ethical enterprise complying with all the legal regulatory rules to provide service to the society. HIV_COVID-19 HGM BioBank has been repurposed to offer an important resource for global research of COVID-19 in newborns, children, adolescents, adults and elders to study the biological effect of the pandemic. CONCLUSION Herein, we present a description of how HIV HGM BioBank has rapidly become an indispensable structure in modern biomedical research, including COVID-19 research.
Collapse
Affiliation(s)
- Consuegra Irene
- Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
- HIV HGM BioBank, Madrid, Spain
| | - Mauleón Elba
- Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
- HIV HGM BioBank, Madrid, Spain
| | - José Luis Jiménez
- Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
- HIV HGM BioBank, Madrid, Spain
- Plataforma-Laboratorio (IiSGM), Madrid, Spain
| | - María José Mellado
- General Pediatrics, Infectious and Tropical Diseases Department Hospital, Universitario La Paz, Madrid, Spain
| | - María Ángeles Muñoz-Fernández
- Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
- HIV HGM BioBank, Madrid, Spain.
- Laboratorio InmunoBiología Molecular (HGUGM), Madrid, Spain.
- Head Immunology Section, Hospital General Universitario Gregorio Marañón, C/Dr. Esquerdo 46, 28007, Madrid, Spain.
| |
Collapse
|
5
|
Zhu Y, Jackson D, Hunter B, Beattie L, Turner L, Hambly BD, Jeremy RW, Malecki C, Robertson EN, Li A, Remedios C, Richmond D, Semsarian C, O'Sullivan JF, Bannon PG, Lal S. Models of cardiovascular surgery biobanking to facilitate translational research and precision medicine. ESC Heart Fail 2021; 9:21-30. [PMID: 34931483 PMCID: PMC8787984 DOI: 10.1002/ehf2.13768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2021] [Revised: 11/07/2021] [Accepted: 12/02/2021] [Indexed: 11/17/2022] Open
Abstract
Biobanking in health care has evolved over the last few decades from simple biological sample repositories to complex and dynamic units with multi‐organizational infrastructure networks and has become an essential tool for modern medical research. Cardiovascular tissue biobanking provides a unique opportunity to utilize cardiac and vascular samples for translational research into heart failure and other related pathologies. Current techniques for diagnosis, classification, and treatment monitoring of cardiac disease relies primarily on interpretation of clinical signs, imaging, and blood biomarkers. Further research at the disease source (i.e. myocardium and blood vessels) has been limited by a relative lack of access to quality human cardiac tissue and the inherent shortcomings of most animal models of heart disease. In this review, we describe a model for cardiovascular tissue biobanking and databasing, and its potential to facilitate basic and translational research. We share techniques to procure endocardial samples from patients with hypertrophic cardiomyopathy, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction, in addition to aortic disease samples. We discuss some of the issues with respect to data collection, privacy, biobank consent, and the governance of tissue biobanking. The development of tissue biobanks as described here has significant scope to improve and facilitate translational research in multi‐omic fields such as genomics, transcriptomics, proteomics, and metabolomics. This research heralds an era of precision medicine, in which patients with cardiovascular pathology can be provided with optimized and personalized medical care for the treatment of their individual phenotype.
Collapse
Affiliation(s)
- YingYan Zhu
- Department of Cardiothoracic Surgery Royal Prince Alfred Hospital Sydney New South Wales Australia
| | - Dan Jackson
- Department of Cardiothoracic Surgery Royal Prince Alfred Hospital Sydney New South Wales Australia
| | - Benjamin Hunter
- Cardiovascular Precision Laboratory The University of Sydney Sydney New South Wales 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney New South Wales Australia
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
| | - Lorna Beattie
- Department of Cardiothoracic Surgery Royal Prince Alfred Hospital Sydney New South Wales Australia
- The Baird Institute for Applied Heart and Lung Surgical Research Sydney New South Wales Australia
| | - Lisa Turner
- Department of Cardiothoracic Surgery Royal Prince Alfred Hospital Sydney New South Wales Australia
- The Baird Institute for Applied Heart and Lung Surgical Research Sydney New South Wales Australia
| | - Brett D. Hambly
- Charles Perkins Centre The University of Sydney Sydney New South Wales Australia
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
| | - Richmond W. Jeremy
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- The Baird Institute for Applied Heart and Lung Surgical Research Sydney New South Wales Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney New South Wales Australia
| | - Cassandra Malecki
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
| | - Elizabeth N. Robertson
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney New South Wales Australia
| | - Amy Li
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- Department of Pharmacy & Biomedical Sciences La Trobe University Melbourne Victoria Australia
| | - Cris Remedios
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
| | - David Richmond
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney New South Wales Australia
| | - Christopher Semsarian
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney New South Wales Australia
- Agnes Ginges Centre for Molecular Cardiology Centenary Institute Sydney New South Wales Australia
| | - John F. O'Sullivan
- Cardiovascular Precision Laboratory The University of Sydney Sydney New South Wales 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney New South Wales Australia
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney New South Wales Australia
- Heart Research Institute The University of Sydney Sydney New South Wales Australia
| | - Paul G. Bannon
- Department of Cardiothoracic Surgery Royal Prince Alfred Hospital Sydney New South Wales Australia
- Charles Perkins Centre The University of Sydney Sydney New South Wales Australia
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- The Baird Institute for Applied Heart and Lung Surgical Research Sydney New South Wales Australia
- RPA Institute of Academic Surgery (IAS) Royal Prince Alfred Hospital and the University of Sydney Sydney New South Wales Australia
| | - Sean Lal
- Cardiovascular Precision Laboratory The University of Sydney Sydney New South Wales 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney New South Wales Australia
- Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
- The Baird Institute for Applied Heart and Lung Surgical Research Sydney New South Wales Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney New South Wales Australia
| |
Collapse
|
6
|
Gramatiuk SM, Bagmut IY, Sheremet MI, Sargsyan K, Yushko AM, Filipchenko SM, Maksymyuk VV, Tarabanchuk VV, Moroz PV, Popovich AI. Pediatric biobanks and parents of disabled children associations opinions on establishing children repositories in developing countries. J Med Life 2021; 14:50-55. [PMID: 33767785 PMCID: PMC7982269 DOI: 10.25122/jml-2020-0106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Pediatric biobanks are an indispensable resource for the research needed to bring advances in personalized medicine into pediatric medical care. It is unclear how or when these advances in medical care may reach children, but it is unlikely that research in adults will be adequate. We conducted the screening for a hypothetic problem in various European and American pediatric biobanks based on online surveys through e-mail distribution based on the Biobank Economic Modeling Tool (BEMT) questionnaire model. Participants in the survey had work experience in biobanking for at least 3 years or more. Contact information about the survey participants was confirmed on the social networks profiles (LinkedIn), as well as on generally available websites. First, we tried creating a model which can show the pediatric preclinical and basic clinical phase relationship and demonstrate how pediatric biobanking is linked to this process. Furthermore, we tried to look for new trends, and the final goal is to put the acquired knowledge into practice, so medical experts and patients could gain usable benefit from it. We concluded that leading positions must take into account ethical and legal aspects when considering the decision to include children in the biobank collection. However, communication with parents and children is essential. The biobank characteristics influence the biobank's motives to include children in the consent procedure. Moreover, the motives to include children influence how the children are involved in the consent procedure and the extent to which children are able to make voluntary decisions as part of the consent procedure.
Collapse
Affiliation(s)
| | | | | | | | - Alla Mironovna Yushko
- Ukraine Association of Biobank, Institute of Cellular Biorehabilitation, Kharkiv, Ukraine.,Yaroslav Mudryi National Law University, Kharkiv, Ukraine
| | | | | | | | | | - Andriy Ivanovich Popovich
- Department of Pathology (Pathology and Forensic Medicine), Bukovinian State Medical University, Chernivtsi, Ukraine
| |
Collapse
|
7
|
Lucas S, Tencerova M, von der Weid B, Andersen TL, Attané C, Behler-Janbeck F, Cawthorn WP, Ivaska KK, Naveiras O, Podgorski I, Reagan MR, van der Eerden BCJ. Guidelines for Biobanking of Bone Marrow Adipose Tissue and Related Cell Types: Report of the Biobanking Working Group of the International Bone Marrow Adiposity Society. Front Endocrinol (Lausanne) 2021; 12:744527. [PMID: 34646237 PMCID: PMC8503265 DOI: 10.3389/fendo.2021.744527] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 08/24/2021] [Indexed: 12/19/2022] Open
Abstract
Over the last two decades, increased interest of scientists to study bone marrow adiposity (BMA) in relation to bone and adipose tissue physiology has expanded the number of publications using different sources of bone marrow adipose tissue (BMAT). However, each source of BMAT has its limitations in the number of downstream analyses for which it can be used. Based on this increased scientific demand, the International Bone Marrow Adiposity Society (BMAS) established a Biobanking Working Group to identify the challenges of biobanking for human BMA-related samples and to develop guidelines to advance establishment of biobanks for BMA research. BMA is a young, growing field with increased interest among many diverse scientific communities. These bring new perspectives and important biological questions on how to improve and build an international community with biobank databases that can be used and shared all over the world. However, to create internationally accessible biobanks, several practical and legislative issues must be addressed to create a general ethical protocol used in all institutes, to allow for exchange of biological material internationally. In this position paper, the BMAS Biobanking Working Group describes similarities and differences of patient information (PIF) and consent forms from different institutes and addresses a possibility to create uniform documents for BMA biobanking purposes. Further, based on discussion among Working Group members, we report an overview of the current isolation protocols for human bone marrow adipocytes (BMAds) and bone marrow stromal cells (BMSCs, formerly mesenchymal), highlighting the specific points crucial for effective isolation. Although we remain far from a unified BMAd isolation protocol and PIF, we have summarized all of these important aspects, which are needed to build a BMA biobank. In conclusion, we believe that harmonizing isolation protocols and PIF globally will help to build international collaborations and improve the quality and interpretation of BMA research outcomes.
Collapse
Affiliation(s)
- Stephanie Lucas
- Marrow Adiposity and Bone Lab-MABLab ULR4490, Univ. Littoral Côte d’Opale, Boulogne-sur-Mer, Univ. Lille, CHU Lille, Lille, France
| | - Michaela Tencerova
- Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia
| | - Benoit von der Weid
- School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Swiss Institute of Bioinformatics, Lausanne, Switzerland
- Department of Biomedical Sciences, Faculty of Biology and Medicine, Université de Lausanne, Lausanne, Switzerland
| | - Thomas Levin Andersen
- Clinical Cell Biology, Department of Pathology, Odense University Hospital, Odense, Denmark
- Clinical Cell Biology, Pathology Research Unit, Department of Clinical Research, University of Southern Denmark, Odense, Denmark
- Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark
- Department of Forensic Medicine, Aarhus University, Aarhus, Denmark
| | - Camille Attané
- Institute of Pharmacology and Structural Biology, Université de Toulouse, CNRS UMR 5089, Toulouse, France
- Equipe labellisée Ligue contre le cancer, Toulouse, France
| | - Friederike Behler-Janbeck
- Department of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Department of Orthopedics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - William P. Cawthorn
- British Heart Foundation Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom
| | - Kaisa K. Ivaska
- Institute of Biomedicine, University of Turku, Turku, Finland
| | - Olaia Naveiras
- Department of Biomedical Sciences, Faculty of Biology and Medicine, Université de Lausanne, Lausanne, Switzerland
- Hematology Service, Departments of Oncology and Laboratory Medicine, Lausanne University Hospital (CHUV), Université de Lausanne, Lausanne, Switzerland
| | - Izabela Podgorski
- Department of Pharmacology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, MI, United States
| | - Michaela R. Reagan
- Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME, United States
- Graduate School for Biomedical Science, Tufts University, Boston, MA, United States
| | - Bram C. J. van der Eerden
- Laboratory for Calcium and Bone Metabolism, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands
- *Correspondence: Bram C. J. van der Eerden,
| |
Collapse
|
8
|
Future-proofing biobanks' governance. Eur J Hum Genet 2020; 28:989-996. [PMID: 32424324 PMCID: PMC7468350 DOI: 10.1038/s41431-020-0646-4] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Revised: 03/27/2020] [Accepted: 04/28/2020] [Indexed: 12/30/2022] Open
Abstract
Good biobank governance implies—at a minimum—transparency and accountability and the implementation of oversight mechanisms. While the biobanking community is in general committed to such principles, little is known about precisely which governance strategies biobanks adopt to meet those objectives. We conducted an exploratory analysis of governance mechanisms adopted by research biobanks, including genetic biobanks, located in Europe and Canada. We reviewed information available on the websites of 69 biobanks, and directly contacted them for additional information. Our study identified six types of commonly adopted governance strategies: communication, compliance, expert advice, external review, internal procedures, and partnerships. Each strategy is implemented through different mechanisms including, independent ethics assessment, informed consent processes, quality management, data access control, legal compliance, standard operating procedures and external certification. Such mechanisms rely on a wide range of bodies, committees and actors from both within and outside the biobanks themselves. We found that most biobanks aim to be transparent about their governance mechanisms, but could do more to provide more complete and detailed information about them. In particular, the retrievable information, while showing efforts to ensure biobanks operate in a legitimate way, does not specify in sufficient detail how governance mechanisms support accountability, nor how they ensure oversight of research operations. This state of affairs can potentially undermine biobanks’ trustworthiness to stakeholders and the public in a long-term perspective. Given the ever-increasing reliance of biomedical research on large biological repositories and their associated databases, we recommend that biobanks increase their efforts to future-proof their governance.
Collapse
|
9
|
Kongsholm NCH, Christensen ST, Hermann JR, Larsen LA, Minssen T, Pedersen LB, Rajam N, Tommerup N, Tupasela A, Schovsbo J. Challenges for the Sustainability of University-Run Biobanks. Biopreserv Biobank 2018; 16:312-321. [DOI: 10.1089/bio.2018.0054] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Affiliation(s)
| | - Søren Tvorup Christensen
- Section of Cell Biology and Physiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark
| | - Janne Rothmar Hermann
- Center for Advanced Studies in Biomedical Innovation Law (CeBIL), University of Copenhagen, Copenhagen, Denmark
| | - Lars Allan Larsen
- Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Timo Minssen
- Center for Advanced Studies in Biomedical Innovation Law (CeBIL), University of Copenhagen, Copenhagen, Denmark
| | - Lotte Bang Pedersen
- Section of Cell Biology and Physiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark
| | - Neethu Rajam
- Center for Information and Innovation Law (CIIR), University of Copenhagen, Copenhagen, Denmark
| | - Niels Tommerup
- Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Aaro Tupasela
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Jens Schovsbo
- Center for Information and Innovation Law (CIIR), University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
10
|
Zatloukal K, Stumptner C, Kungl P, Mueller H. Biobanks in personalized medicine. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT 2018. [DOI: 10.1080/23808993.2018.1493921] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
- Kurt Zatloukal
- Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria
| | - Cornelia Stumptner
- Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria
| | - Penelope Kungl
- Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria
| | - Heimo Mueller
- Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria
| |
Collapse
|
11
|
Chan TW, Ho CWL. A Ten-Year Retrospective Analysis of Consent for the Donation of Residual Human Tissue in a Singapore Healthcare Institution: Reflections on Governance. Asian Bioeth Rev 2017. [DOI: 10.1007/s41649-017-0040-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
|
12
|
Reznik ON, Kuzmin DO, Reznik AO. Biobanks as the basis for developing biomedicine: Problems and prospects. Mol Biol 2017. [DOI: 10.1134/s0026893317050156] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
13
|
Gee S, Oliver R, Corfield J, Georghiou L, Yuille M. Biobank Finances: A Socio-Economic Analysis and Review. Biopreserv Biobank 2016; 13:435-51. [PMID: 26697914 DOI: 10.1089/bio.2015.0030] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
This socio-economic study is based on the widely held view that there is an inadequate supply of human biological samples that is hampering biomedical research development and innovation (RDI). The potential value of samples and the associated data are thus not being realized. We aimed to examine whether the financing of biobanks contributes to this problem and then to propose a national solution. We combined three methods: a qualitative case study; literature analysis; and informal consultations with experts. The case study enabled an examination of the complex institutional arrangements for biobanks, with a particular focus on cost models. For the purposes of comparison, a typology for biobanks was developed using the three methods. We found that it is not possible to apply a standard cost model across the diversity of biobanks, and there is a deficit in coordination and sustainability and an excess of complexity. We propose that coordination across this diversity requires dedicated resources for a national biobanking distributed research infrastructure. A coordination center would establish and improve standards and support a national portal for access. This should be financed centrally by public funds, possibly supplemented by industrial funding. We propose that: a) sample acquisition continues to be costed into projects and project proposals to ensure biobanking is driven by research needs; b) core biobanking activities and facilities be supported by central public funds distributed directly to host public institutions; and c) marginal costs for access be paid for by the user.
Collapse
Affiliation(s)
- Sally Gee
- 1 Manchester Institute of Innovation Research, Manchester Business School, The University of Manchester , Manchester, United Kingdom
| | - Rob Oliver
- 2 Research and Development Directorate, Salford Royal Hospitals NHS Trust , Salford, United Kingdom
| | | | - Luke Georghiou
- 1 Manchester Institute of Innovation Research, Manchester Business School, The University of Manchester , Manchester, United Kingdom
| | - Martin Yuille
- 4 Center for Integrated Genomic Medical Research, Institute of Population Health, The University of Manchester , Manchester, United Kingdom
| |
Collapse
|
14
|
|
15
|
Kaye J, Briceño Moraia L, Mitchell C, Bell J, Bovenberg JA, Tassé AM, Knoppers BM. Access Governance for Biobanks: The Case of the BioSHaRE-EU Cohorts. Biopreserv Biobank 2016; 14:201-6. [PMID: 27183185 PMCID: PMC5939924 DOI: 10.1089/bio.2015.0124] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Currently, researchers have to apply separately to individual biobanks if they want to carry out studies that use samples and data from multiple biobanks. This article analyzes the access governance arrangements of the original five biobank members of the Biobank Standardisation and Harmonisation for Research Excellence in the European Union (BioSHaRE-EU) project in Finland, Germany, the Netherlands, Norway, and the United Kingdom to identify similarities and differences in policies and procedures, and consider the potential for internal policy “harmonization.” Our analysis found differences in the range of researchers and organizations eligible to access biobanks; application processes; requirements for Research Ethics Committee approval; and terms of Material Transfer Agreements relating to ownership and commercialization. However, the main elements of access are the same across biobanks; access will be granted to bona fide researchers conducting research in the public interest, and all biobanks will consider the scientific merit of the proposed use and it's compatibility with the biobank's objectives. These findings suggest potential areas for harmonization across biobanks. This could be achieved through a single centralized application to a number of biobanks or a system of mutual recognition that places a presumption in favor of access to one biobank if already approved by another member of the same consortium. Biobanking and Biomolecular Resources Research Infrastructure-European Research Infrastructure Consortia (BBMRI-ERIC), a European consortium of biobanks and bioresources with its own ethical, legal, and social implications (ELSI) common service, could provide a platform by developing guidelines for harmonized internal processes.
Collapse
Affiliation(s)
- Jane Kaye
- 1 HeLEX Centre for Health, Law and Emerging Technologies, Nuffield Department of Population Health, University of Oxford , Oxford, United Kingdom
| | - Linda Briceño Moraia
- 1 HeLEX Centre for Health, Law and Emerging Technologies, Nuffield Department of Population Health, University of Oxford , Oxford, United Kingdom
| | - Colin Mitchell
- 1 HeLEX Centre for Health, Law and Emerging Technologies, Nuffield Department of Population Health, University of Oxford , Oxford, United Kingdom
| | - Jessica Bell
- 1 HeLEX Centre for Health, Law and Emerging Technologies, Nuffield Department of Population Health, University of Oxford , Oxford, United Kingdom
| | | | - Anne-Marie Tassé
- 3 Public Population Project in Genomics and Society (P3G) , Montreal, Canada
| | - Bartha Maria Knoppers
- 3 Public Population Project in Genomics and Society (P3G) , Montreal, Canada .,4 Centre of Genomics and Policy, McGill University , Montreal, Canada
| |
Collapse
|
16
|
García-Merino IM, Consuegra I, Jiménez JL, Muñoz-Fernández MÁ. Specific legislation on biobanks in Spain. Biopreserv Biobank 2016; 13:207-11. [PMID: 26035011 DOI: 10.1089/bio.2014.0070] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Spain has enacted specific legislation concerning biobanks. This legislation regulates how biobanks should be set up, how they should operate, and the requirements they need to comply with. The main objective of this legislation is to keep a good balance between scientific progress and respect for the rights and freedom of individuals participating in research. Therefore, this legislation lays down a series of basic principles, for instance, the principle to inform donors accurately i) on the deposit of samples in terms of the objectives and implications of their donation and on the need to obtain written consents; ii) on the obligation to establish consistent procedures to guarantee the confidentiality of personal data associated with and obtained from biological samples; iii) on the concept of free sample donation either by donors or by biobanks; iv) on the need for consistent procedures to deposit samples and data in biobanks; and v) for acts of donation and data for research projects to be performed correctly. Although this Spanish legislation fulfills its objectives, it has some drawbacks; mainly it overprotects research participants. This issue should be analyzed in future revisions of the legislation.
Collapse
Affiliation(s)
- Isabel Ma García-Merino
- Hospital General Universitario Gregorio Marañón. BioBanco VIH HGM, Plataforma de Laboratorio. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - Irene Consuegra
- Hospital General Universitario Gregorio Marañón. BioBanco VIH HGM, Plataforma de Laboratorio. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - José Luís Jiménez
- Hospital General Universitario Gregorio Marañón. BioBanco VIH HGM, Plataforma de Laboratorio. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - Ma Ángeles Muñoz-Fernández
- Hospital General Universitario Gregorio Marañón. BioBanco VIH HGM, Plataforma de Laboratorio. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| |
Collapse
|
17
|
Kinkorová J. Biobanks in the era of personalized medicine: objectives, challenges, and innovation: Overview. EPMA J 2016; 7:4. [PMID: 26904153 PMCID: PMC4762166 DOI: 10.1186/s13167-016-0053-7] [Citation(s) in RCA: 89] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Accepted: 01/24/2016] [Indexed: 11/10/2022]
Abstract
Biobanks are an important compound of personalized medicine and strongly support the scientific progress in stratification of population and biomarker discovery and validation due to progress in personalized medicine. Biobanks are an essential tool for new drug discoveries and drug development. Biobanks play an important role in the whole process of patient prevention and prediction, follow-up, and therapy monitoring and optimalization. Biobanks have the specificity in that they cover multidisciplinary approach to the human health combining biological and medical approaches, as well as informative bioinformatics technologies, computationing, and modeling. The importance of biobanks has during the last decade increased in variety and capacity from small collections of samples to large-scale national or international repositories. Collected samples are population-based, disease-specific or rare diseases originating from a diverse profile of individuals. There are various purposes of biobanks, such as diagnostics, pharmacology, or research. Biobanks involve, store, and operate with specific personal information, and as a consequence, such a diversity of biobanking is associated with a broad spectrum of ethical and legal issues. Biobanks are an international phenomenon because any single country, state, or society at the moment is not able to cover all issues involving the whole biobank problematic. Biobanks have an enormous innovative potential in the whole process of biomedical research in the twenty-first century.
Collapse
Affiliation(s)
- Judita Kinkorová
- Faculty Hospital in Pilsen, Edvarda Benese 1128/13, 305 99 Plzen, Czech Republic
- Medical Faculty Charles University in Pilsen, Lidicka 1, 301 00 Plzen, Czech Republic
| |
Collapse
|
18
|
Engelmark MT, Beskow AH. Analysis of the research sample collections of Uppsala biobank. Biopreserv Biobank 2015; 12:325-31. [PMID: 25340941 DOI: 10.1089/bio.2014.0025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Uppsala Biobank is the joint and only biobank organization of the two principals, Uppsala University and Uppsala University Hospital. Biobanks are required to have updated registries on sample collection composition and management in order to fulfill legal regulations. We report here the results from the first comprehensive and overall analysis of the 131 research sample collections organized in the biobank. The results show that the median of the number of samples in the collections was 700 and that the number of samples varied from less than 500 to over one million. Blood samples, such as whole blood, serum, and plasma, were included in the vast majority, 84.0%, of the research sample collections. Also, as much as 95.5% of the newly collected samples within healthcare included blood samples, which further supports the concept that blood samples have fundamental importance for medical research. Tissue samples were also commonly used and occurred in 39.7% of the research sample collections, often combined with other types of samples. In total, 96.9% of the 131 sample collections included samples collected for healthcare, showing the importance of healthcare as a research infrastructure. Of the collections that had accessed existing samples from healthcare, as much as 96.3% included tissue samples from the Department of Pathology, which shows the importance of pathology samples as a resource for medical research. Analysis of different research areas shows that the most common of known public health diseases are covered. Collections that had generated the most publications, up to over 300, contained a large number of samples collected systematically and repeatedly over many years. More knowledge about existing biobank materials, together with public registries on sample collections, will support research collaborations, improve transparency, and bring us closer to the goals of biobanks, which is to save and prolong human lives and improve health and quality of life.
Collapse
Affiliation(s)
- Malin T Engelmark
- Uppsala Biobank, Uppsala County Council and Uppsala University , Uppsala, Sweden
| | | |
Collapse
|
19
|
Roessler BJ, Steneck NH, Connally L. The MICHR Genomic DNA BioLibrary: An Empirical Study of the Ethics of Biorepository Development. J Empir Res Hum Res Ethics 2015; 10:37-48. [PMID: 25742665 DOI: 10.1177/1556264614564975] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
In this article, we report on an effort to study the development and usefulness of a large, broad-use, opt-in biorepository for genomic research, focusing on three ethical issues: providing appropriate understanding, recruiting in ways that do not comprise autonomous decisions, and assessing costs versus benefits. We conclude the following: (a) Understanding can be improved by separating the task of informing subjects from documenting informed consent (Common Rule) and permission to use personal health information and samples for research (Health Insurance Portability and Accountability Act [HIPAA]); however, regulations might have to be changed to accommodate this approach. (b) Changing recruiting methods increases efficiency but can interfere with subject autonomy. (c) Finally, we propose a framework for the objective evaluation of the utility of biorepositories and suggest that more attention needs to be paid to use and sustainability.
Collapse
Affiliation(s)
- Blake J Roessler
- Michigan Institute for Clinical and Health Research (MICHR), University of Michigan Medical School, Ann Arbor, Michigan, USA Division of Rheumatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
| | - Nicholas H Steneck
- Michigan Institute for Clinical and Health Research (MICHR), University of Michigan Medical School, Ann Arbor, Michigan, USA Department of History, College of Literature, Science and the Arts, University of Michigan, Ann Arbor, Michigan, USA
| | - Lisa Connally
- Michigan Institute for Clinical and Health Research (MICHR), University of Michigan Medical School, Ann Arbor, Michigan, USA
| |
Collapse
|
20
|
|
21
|
Tamminen S. Bio-objectifying European bodies: standardisation of biobanks in the Biobanking and Biomolecular Resources Research Infrastructure. LIFE SCIENCES, SOCIETY AND POLICY 2015; 11:13. [PMID: 26626620 PMCID: PMC4666881 DOI: 10.1186/s40504-015-0031-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/23/2015] [Accepted: 11/18/2015] [Indexed: 05/04/2023]
Abstract
The article traces the genealogy of the Minimum Information About Biobank Data Sharing model, created in the European Biobanking and Biomolecular Resources Research Infrastructure to facilitate collaboration among biobanks and to foster the exchange of biological samples and data. This information model is aimed at the identification of biobanks; unification of databases; and objectification of the information, samples, and related studies - to create a completely new 'bio-object infrastructure' within the EU. The paper discusses key challenges in creating a 'universal' information model of such a kind, the most important technical translations of European research policy needed for a standardised model for biobank information, and how this model creates new bio-objects. The author claims that this amounts to redefinition of biobanks and technical governance over virtually bio-objectified European populations. It is argued here that old governance models based on the nation-state need radical reconsideration so that we are prepared for a new and changing situation wherein bodies of information that lack organs flow from one database to another with a click of a mouse.
Collapse
Affiliation(s)
- Sakari Tamminen
- Department of Social Research, University of Helsinki, P.O. Box 54, Helsinki, 00014, Finland.
| |
Collapse
|
22
|
Minssen T, Schovsbo J. Legal aspects of biobanking as key issues for personalized medicine and translational exploitation. Per Med 2014; 11:497-508. [DOI: 10.2217/pme.14.29] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
This perspective article provides an overview on selected legal aspects of biobanking. It discusses these issues with a focus on public biobanks in a university setting and the specific challenges posed by personalized medicine. We conclude that any decisions as to the design of the regulatory environment should follow a process that takes account of the values, hopes and concerns of all stakeholders involved. In particular, we stress the importance of a careful planning of consent obligations combining traditional legal methods with an adequate institutional setup. In order to enhance the translational exploitation of biobanks, we further emphasize the pressing need to carefully consider a great variety of strategies and policy choices relating to intellectual property rights.
Collapse
Affiliation(s)
- Timo Minssen
- Centre for Information & Innovation Law (CIIR), University of Copenhagen, Faculty of Law, Studiegården, Studiestræde 6, 1455 Copenhagen, Denmark
| | - Jens Schovsbo
- Centre for Information & Innovation Law (CIIR), University of Copenhagen, Faculty of Law, Studiegården, Studiestræde 6, 1455 Copenhagen, Denmark
| |
Collapse
|
23
|
Branković I, Malogajski J, Morré SA. Biobanking and translation of human genetics and genomics for infectious diseases. Appl Transl Genom 2014; 3:30-5. [PMID: 27275411 PMCID: PMC4881987 DOI: 10.1016/j.atg.2014.04.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2014] [Revised: 02/22/2014] [Accepted: 04/02/2014] [Indexed: 11/21/2022]
Abstract
Biobanks are invaluable resources in genomic research of both the infectious diseases and their hosts. This article examines the role of biobanks in basic research of infectious disease genomics, as well as the relevance and applicability of biobanks in the translation of impending knowledge and the clinical uptake of knowledge of infectious diseases. Our research identifies potential fields of interaction between infectious disease genomics and biobanks, in line with global trends in the integration of genome-based knowledge into clinical practice. It also examines various networks and biobanks that specialize in infectious diseases (including HIV, HPV and Chlamydia trachomatis), and provides examples of successful research and clinical uptake stemming from these biobanks. Finally, it outlines key issues with respect to data privacy in infectious disease genomics, as well as the utility of adequately designed and maintained electronic health records. We maintain that the public should be able to easily access a clear and detailed outline of regulations and procedures for sample and data utilization by academic or commercial investigators, and also should be able to understand the precise roles of relevant governing bodies. This would ultimately facilitate uptake by researchers and clinics. As a result of the efforts and resources invested by several networks and consortia, there is an increasing awareness of the prospective uses of biobanks in advancing infectious disease genomic research, diagnostics and their clinical management. The role of biobanks in research of host genomic factors and infectious diseases. Examples of translation of HIV, HPV and Chlamydia research results into clinics. Lack of published overviews of infectious disease biobanks, result is low visibility. Regulations and sample utilization procedures should be more easily accessible.
Collapse
Affiliation(s)
- Ivan Branković
- Institute for Public Health Genomics, Department of Genetics and Cell Biology, Research School GROW, Maastricht University, Maastricht, The Netherlands
| | - Jelena Malogajski
- Institute for Public Health Genomics, Department of Genetics and Cell Biology, Research School GROW, Maastricht University, Maastricht, The Netherlands
| | - Servaas A Morré
- Institute for Public Health Genomics, Department of Genetics and Cell Biology, Research School GROW, Maastricht University, Maastricht, The Netherlands; Laboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands
| |
Collapse
|
24
|
Affiliation(s)
- Ozren Polasek
- Ozren Polasek, Centre for Global Health, Medical School, University of Split, Split, Croatia,
| |
Collapse
|
25
|
Chen H, Gottweis H, Starkbaum J. Public Perceptions of Biobanks in China: A Focus Group Study. Biopreserv Biobank 2013; 11:267-71. [DOI: 10.1089/bio.2013.0016] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Haidan Chen
- College of Humanities and Development Studies, China Agricultural University, Beijing
| | - Herbert Gottweis
- Department of Political Science, Life-Science-Governance Research Platform, University of Vienna, Austria
- Department of Sociology, Kyung Hee University, Seoul, South Korea
| | - Johannes Starkbaum
- Department of Political Science, Life-Science-Governance Research Platform, University of Vienna, Austria
| |
Collapse
|
26
|
Knoppers BM, Zawati MH, Kirby ES. Sampling Populations of Humans Across the World: ELSI Issues. Annu Rev Genomics Hum Genet 2012; 13:395-413. [DOI: 10.1146/annurev-genom-090711-163834] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Bartha Maria Knoppers
- Centre of Genomics and Policy, McGill University and Genome Quebec Innovation Centre, Montreal, Quebec H3A 1A4, Canada; , ,
| | - Ma'n H. Zawati
- Centre of Genomics and Policy, McGill University and Genome Quebec Innovation Centre, Montreal, Quebec H3A 1A4, Canada; , ,
| | - Emily S. Kirby
- Centre of Genomics and Policy, McGill University and Genome Quebec Innovation Centre, Montreal, Quebec H3A 1A4, Canada; , ,
| |
Collapse
|
27
|
Laurie G. Reflexive governance in biobanking: on the value of policy led approaches and the need to recognise the limits of law. Hum Genet 2011; 130:347-56. [PMID: 21766192 DOI: 10.1007/s00439-011-1066-x] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2011] [Accepted: 07/05/2011] [Indexed: 11/28/2022]
Abstract
Although a few jurisdictions around the world have legislated in response to the phenomenon of biobanking, the far more common response has been policy led with funders and other stakeholders initiating multi-level policy initiatives to guide biobanking practice. An example of this is UK Biobank which has developed and operates according to an Ethics and Governance Framework. Such an instrument has no basis in law and yet it has played a crucial role in the set up and ongoing management of the resource. It will continue to do so, as related policies emerge, such as access and intellectual property policies. Numerous biobanking initiatives have similar high-level policy documents that guide decisions and practice. These are often framed as a commitment to participants, researchers and society more broadly and invoke notions such as the public good and the public interest. As such, they serve as a benchmark against which to measure a biobank's performance. Moreover, policies become an important means by which biobankers are held accountable. This article critically analyses this policy-driven phenomenon asking how effectively policy--often as an alternative to law--serves to police and to promote biobanking. It argues that a policy of reflexive governance--defined and developed herein--can best meet the challenges faced by many biobanks and without the need for recourse to law.
Collapse
Affiliation(s)
- Graeme Laurie
- The Arts and Humanities Research Council, Research Centre for Studies in Intellectual Property and Technology Law, School of Law, University of Edinburgh, Old College, South Bridge, Edinburgh EH8-9YL, Scotland, UK.
| |
Collapse
|
28
|
Morente MM, Cereceda L, Luna-Crespo F, Artiga MJ. Managing a Biobank Network. Biopreserv Biobank 2011; 9:187-90. [DOI: 10.1089/bio.2011.0005] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Manuel M. Morente
- Tumour Bank Unit, Spanish National Tumour Bank Network, Molecular Pathology Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain
- Spanish National Biobank Network Coordination Office, Instituto de Salud Carlos III (Spanish National Institute of Health Carlos III), Madrid, Spain
| | - Laura Cereceda
- Tumour Bank Unit, Spanish National Tumour Bank Network, Molecular Pathology Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain
| | - Francisco Luna-Crespo
- Spanish National Biobank Network Coordination Office, Instituto de Salud Carlos III (Spanish National Institute of Health Carlos III), Madrid, Spain
| | - Maria J. Artiga
- Tumour Bank Unit, Spanish National Tumour Bank Network, Molecular Pathology Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain
| |
Collapse
|
29
|
Abstract
PURPOSE OF REVIEW Biobanking has been identified as a key area for development in order to accelerate the discovery and development of new drugs. This review describes the recent advances in the field of biobanking and biospecimen research, with special reference to tumour banks which are the biobanks of primary interest in oncology. RECENT FINDINGS There is a dramatic deficiency of high-quality, well annotated cancer biospecimens. Biospecimen research is a fast developing field that will improve biobanking methodology and biobanking is becoming more professionally organized with increased attention to quality management. Biobank networks are developing rapidly in order to combine and share resources. SUMMARY Biobanking services must improve rapidly to serve the needs of personalized medicine and biospecimen research should be encouraged and supported at all levels from project funding to publication of results. Biobanks need to be run to high professional standards and the importance of adequate funding, training and certification must be emphasized. The growing presence of national and international biobank networks will allow biobanks to synergize. The development of a biobanking community will facilitate teamwork to overcome common challenges and enhance communication with multiple stakeholder groups.
Collapse
|
30
|
Hoeyer K. The ethics of research biobanking: a critical review of the literature. Biotechnol Genet Eng Rev 2011; 25:429-52. [PMID: 21412365 DOI: 10.5661/bger-25-429] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Human tissue has been stored and used for research on a regular basis for more than 80 years. During the 1990s, collections of human tissue suddenly became framed as ethical problems in a process reflecting developments in genetic research intertwined with developments in patient rights and steps towards increased commercialization of research. This review describes the process of framing tissue storage as an ethical problem and the solutions proposed in the process. It gives an overview of the academic debate and relates this debate to empirical studies of donor attitudes and interests. It points to the clear discrepancy between the concerns of donors, legislators and ethicists. The academic debate and legislatory action tend to focus on informed consent, and most of the concerns that donors have remain unattended to.
Collapse
Affiliation(s)
- Klaus Hoeyer
- University of Copenhagen, Department of Public Health, Unit of Health Services Research, Oester Farimagsgade 5, Building 15, DK-1014 Copenhagen, Denmark.
| |
Collapse
|
31
|
Abstract
A new biobanking method is proposed, wherein samples and associated data would be deposited anonymously and labelled using a PIN code that is produced on the basis of personal biological characteristics, such as single nucleotide polymorphisms. The code would be the 'Bio-PIN' to uniquely distinguish the sample depositors, plus their samples and data. This method could help to diminish several long-discussed ethical, legal and societal problems in biobanking regarding privacy, informed consent, autonomy, data security and public trust.
Collapse
Affiliation(s)
- J J Nietfeld
- Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584CX, The Netherlands.
| | | | | |
Collapse
|
32
|
García-Merino I, de las Cuevas N, Jiménez JL, García A, Gallego J, Gómez C, García D, Muñoz-Fernández MÁ. Pediatric HIV BioBank: a new role of the Spanish HIV BioBank in pediatric HIV research. AIDS Res Hum Retroviruses 2010; 26:241-4. [PMID: 20156108 DOI: 10.1089/aid.2009.0122] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The vulnerability of children has long raised ethical concerns resulting in the lack of inclusion of children in research studies. This has impeded the development of relevant medical therapies specific for children. In response to these circumstances, international policies have begun to recognize the need to carry out research focused on children. Translational HIV infection research is highly dependent on many factors including the availability, quality, and traceability of samples and their associated data under a strict system of quality management. The primary objective of the Pediatric HIV BioBank is to contribute to the furthering of scientific knowledge about vertical HIV infection. To achieve this aim, the BioBank processes, stores, and provides distinct samples from HIV/AIDS children to research projects free of charge. Strict compliance to ethical norms is always guaranteed. At present the Pediatric HIV BioBank has 429 vials containing different sample types from 243 vertically HIV-infected children. The Pediatric HIV BioBank represents a novel approach to HIV research that might be of general interest not only for basic and clinical research teams working with HIV, but also for those groups trying to establish large networks focused on researching specific clinical problems. It also represents a model to stimulate cooperative research on specific clinical problems. The main objective of this article is to show the structure and function of the Pediatric HIV BioBank that allow it to efficiently provide samples to different research projects in Spain and in other countries.
Collapse
Affiliation(s)
- Isabel García-Merino
- Laboratorio de Inmunobiología Molecular, Plataforma de Laboratorio, Hospital General Universitario Gregorio Marañón, Madrid, Spain and Unidad Asociada de Retrovirologia Humana, HGUG-CSIC, Madrid, Spain
| | - Natividad de las Cuevas
- Laboratorio de Inmunobiología Molecular, Plataforma de Laboratorio, Hospital General Universitario Gregorio Marañón, Madrid, Spain and Unidad Asociada de Retrovirologia Humana, HGUG-CSIC, Madrid, Spain
| | - José Luis Jiménez
- Laboratorio de Inmunobiología Molecular, Plataforma de Laboratorio, Hospital General Universitario Gregorio Marañón, Madrid, Spain and Unidad Asociada de Retrovirologia Humana, HGUG-CSIC, Madrid, Spain
| | - Almudena García
- Laboratorio de Inmunobiología Molecular, Plataforma de Laboratorio, Hospital General Universitario Gregorio Marañón, Madrid, Spain and Unidad Asociada de Retrovirologia Humana, HGUG-CSIC, Madrid, Spain
| | - Jorge Gallego
- Laboratorio de Inmunobiología Molecular, Plataforma de Laboratorio, Hospital General Universitario Gregorio Marañón, Madrid, Spain and Unidad Asociada de Retrovirologia Humana, HGUG-CSIC, Madrid, Spain
| | - Coral Gómez
- Laboratorio de Inmunobiología Molecular, Plataforma de Laboratorio, Hospital General Universitario Gregorio Marañón, Madrid, Spain and Unidad Asociada de Retrovirologia Humana, HGUG-CSIC, Madrid, Spain
| | - Dolores García
- Laboratorio de Inmunobiología Molecular, Plataforma de Laboratorio, Hospital General Universitario Gregorio Marañón, Madrid, Spain and Unidad Asociada de Retrovirologia Humana, HGUG-CSIC, Madrid, Spain
| | - M Ángeles Muñoz-Fernández
- Laboratorio de Inmunobiología Molecular, Plataforma de Laboratorio, Hospital General Universitario Gregorio Marañón, Madrid, Spain and Unidad Asociada de Retrovirologia Humana, HGUG-CSIC, Madrid, Spain
| |
Collapse
|
33
|
García-Merino I, de Las Cuevas N, Jiménez JL, Gallego J, Gómez C, Prieto C, Serramía MJ, Lorente R, Muñoz-Fernández MA. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology 2009; 6:27. [PMID: 19272145 PMCID: PMC2667474 DOI: 10.1186/1742-4690-6-27] [Citation(s) in RCA: 132] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2009] [Accepted: 03/09/2009] [Indexed: 11/14/2022] Open
Abstract
Background The collection of samples from HIV-infected patients is the beginning of the chain of translational research. To carry out quality research that could eventually end in a personalized treatment for HIV, it is essential to guarantee the availability, quality and traceability of samples, under a strict system of quality management. Methods The Spanish HIV BioBank was created with the objectives of processing, storing and providing distinct samples from HIV/AIDS patients, categorized according to strictly defined characteristics, free of charge to research projects. Strict compliance to ethical norms is always guaranteed. Results At the moment, the HIV BioBank possesses nearly 50,000 vials containing different prospective longitudinal study sample types. More than 1,700 of these samples are now used in 19 national and international research projects. Conclusion The HIV BioBank represents a novel approach to HIV research that might be of general interest not only for basic and clinical research teams working on HIV, but also for those groups trying to establish large networks focused on research on specific clinical problems. It also represents a model to stimulate cooperative research among large numbers of research groups working as a network on specific clinical problems. The main objective of this article is to show the structure and function of the HIV BioBank that allow it to very efficiently release samples to different research project not only in Spain but also in other countries.
Collapse
|
34
|
Sheedy D, Garrick T, Dedova I, Hunt C, Miller R, Sundqvist N, Harper C. An Australian Brain Bank: a critical investment with a high return! Cell Tissue Bank 2008; 9:205-16. [PMID: 18543078 PMCID: PMC3391553 DOI: 10.1007/s10561-008-9076-1] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2008] [Accepted: 05/18/2008] [Indexed: 11/26/2022]
Abstract
Research into neuropsychiatric disorders, including alcohol-related problems, is limited in part by the lack of appropriate animal models. However, the development of new technologies in pathology and molecular biology means that many more questions can be addressed using appropriately stored human brain tissues. The New South Wales Tissue Resource Centre (TRC) in the University of Sydney (Australia) is a human brain bank that can provide tissues to the neuroscience research community studying alcohol-related brain disorders, schizophrenia, depression and bipolar disorders. Carefully standardised operational protocols and integrated information systems means that the TRC can provide high quality, accurately characterised, tissues for research. A recent initiative, the pre-mortem donor program called "Using our Brains", encourages individuals without neuropsychiatric illness to register as control donors, a critical group for all research. Community support for this program is strong with over 2,000 people registering their interest. Discussed herein are the protocols pertaining to this multifaceted facility and the benefits of investment, both scientific and financial, to neuroscience researchers and the community at large.
Collapse
Affiliation(s)
- D Sheedy
- Discipline of Pathology, University of Sydney, Sydney, NSW 2006, Australia.
| | | | | | | | | | | | | |
Collapse
|
35
|
van Veen EB. Obstacles to European research projects with data and tissue: Solutions and further challenges. Eur J Cancer 2008; 44:1438-50. [DOI: 10.1016/j.ejca.2008.03.011] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2008] [Revised: 03/14/2008] [Accepted: 03/17/2008] [Indexed: 10/22/2022]
|